The “Synthetic Lethality-based Drugs and Targets Market, 2019-2030
Key Inclusions
§ A detailed assessment of the current market landscape,providing information on drug developer(s) (year of establishment, headquartersand size of the company), phase of development (marketed, clinical,preclinical, and discovery stage) of lead candidates, type of molecule (smallmolecule and biologic), type of therapy (monotherapy and combination therapy),type of synlet target, target patient segment, key therapeutic area(s), targetindication(s), and route of administration. In addition, the chapter includes alist of screening platforms that are being used by industry players to studysynlet interactions between gene pairs.
§ Detailed profiles of large players that are engaged in thedevelopment of synthetic lethality-based drugs (shortlisted on the basis ofphase of development of pipeline products), featuring a brief overview of thecompany, its financial information (if available), detailed profiles of theirrespective lead drug candidates, and an informed future outlook. Additionally,each drug profile features information on the type of drug, route ofadministration, target indications, current status of development and anexcerpt on its developmental history. In addition, the chapter includestabulated profiles of small-sized and mid-sized players (shortlisted on thebasis of the number of pipeline products), featuring details on the innovatorcompany (such as location of headquarters, year of establishment, number ofemployees, and key members of the executive team), recent developments, alongwith descriptions of their synthetic lethality-based drug candidates.
§ An analysis of the prevalent and emerging trends in thisdomain, as represented on the social media platform, Twitter, posted during theperiod 2010-2019 (till May), highlighting the historical trend of tweets, mostprolific contributors, frequently discussed synlet targets, popular diseaseindications and a multivariate tweet benchmark analysis.
§ An analysis of close to 700 peer-reviewed scientificarticles related to synthetic lethality, published during the period 2017-2019(till May), highlighting the research focus within this niche industry segment.It includes an informed opinion on the key trends observed across theaforementioned publications, including information on target diseaseindications, synlet targets, and analysis based on various relevant parameters,such as study type (review article, research article and case report), researchobjective, year of publication, key research hubs, most popular authors,provision of grant support, and most popular journals (in terms of number ofarticles published in the given time period and journal impact factor).
§ An analysis of various abstracts presented at the AmericanSociety of Clinical Oncology (ASCO) in the time period 2013-2019 (till May),highlighting several parameters, such as year of (abstract) publication,popular drugs, synlet targets, target cancer indications, popular authors,author designations, industry type (industry and academia) and most activeorganizations (in terms of number of published abstracts). In addition, thisanalysis features a multi-dimensional bubble chart analysis to assess therelative level of expertise of the key authors / researchers based on thenumber of publications, citation count and research gate score.
§ An in-depth analysis of close to 750 grants that have beenawarded to research institutes engaged in projects related to syntheticlethality, between 2014 and 2019 (till May), highlighting various importantparameters associated with grants, such as year of award, support period,amount awarded, funding institute, administration institute center, fundinginstitute center, funding mechanism, spending categorization, grant type,responsible study section, focus area, type of recipient organization andprominent program officers. It also features a detailed analysis on mostpopular synlet targets and target indications, along with a multivariate grantattractiveness analysis based on parameters, such as amount awarded, supportperiod, grant type, number of synlet targets and number of indications understudy.
§ An analysis of the investments made into companies thathave proprietary synthetic lethality-based drugs / screening platforms,including seed financing, venture capital financing, debt financing, grants,capital raised from IPOs and subsequent offerings.
§ An in-depth benchmark analysis of over 230 synlet targetsidentified from various credible sources (research publications, governmentfundings, clinical studies, recent news / tweets and abstracts presented inglobal conferences), highlighting targets that have already been validated inclinical studies, preclinical studies and early-stage research (cases wherethere is no lead (therapeutic) candidate being investigated). Further, ithighlights the long-term opportunities (for drug developers) associated withindividual targets, based on their popularity across different portals.
§ An analysis of the role of innovative companion diagnosticsin synthetic lethality on the basis of several parameters, such as synlettarget, drug candidate(s) being investigated, target biomarker(s), targetdisease indication(s) and assay technique used. It also includes case studies,highlighting those companion diagnostic tests that are available and are beingused to evaluate the therapeutic efficiency of approved PARP inhibitors usingthe principle of synthetic lethality.
§ Informed estimates of the existing market size and thefuture opportunity for synthetic lethality-based drugs and targets, over thenext decade. Based on multiple parameters, such as target consumer segments,region-specific disease prevalence, anticipated adoption of the marketed and latestage drugs and the likely selling price, we have provided informed estimateson the evolution of the market over the period 2019-2030.
The report also features thelikely distribution of the current and forecasted opportunity across importantmarket segments, mentioned below:
§ Typeof Molecule
§ Small Molecule
§ Biologic
§ TargetIndication
§ BreastCancer
§ Cervical/ Anogenital Cancer
§ DiabeticMacular Edema
§ GastricCancer
§ LungCancer
§ OvarianCancer
§ RenalCell Cancer
§ SynletTarget
§ APE/ REF-1
§ CHK1
§ GLS1
§ PARP
§ Polθ
§ WEE1
§ Routeof Administration
§ Oral
§ Intravenous
§ KeyGeographical Regions
§ NorthAmerica
§ Europe
§ Asia-Pacific
§ Restof the World
Thereport includes detailed transcripts of discussions held with the followingexperts:
§ Simon Boulton (VicePresident, Science Strategy, Artios Pharma)
§ Yi Xu (AssociateDirector, Business Development, IMPACT Therapeutics)
§ Norbert Perrimon(Professor, Department of Genetics, Harvard Medical School)
§ Vivek Dharwal(Professor, Department of Biochemistry, Panjab University)
§ Alfred Nijkerk (ChiefExecutive Officer, UbiQ)
To request sample pages, pleasevisit https://www.rootsanalysis.com/reports/267/request-sample.html
Key Questions Answered
§ What are theprevalent R&D trends related to synthetic lethality?
§ What type of clinicalconditions can be treated using synthetic lethality-based drugs?
§ What are the key drugclasses that leverage the concept of synthetic lethality?
§ Whoare the leading industry and non-industry players in this market?
§ Whatare the most popular synlet targets and target indications?
§ Whatare the key geographies where research on synthetic lethality is beingconducted?
§ Whoare the key investors in this domain?
§ Whoare the key opinion leaders / experts in this field?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
Youmay also be interested in the following titles:
1. Global T-Cell (CAR-T, TCR, and TIL)Therapy Market (4th Edition), 2019 – 2030
2. NeoantigenTargeted Therapies Market, 2019-2030
3. Cancer Biomarkers Market: Focus OnTMB, MSI / MMR and TILS Testing, 2019 – 2030
4. Companion Diagnostics Market (2ndEdition), 2019-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
